(406) Axelopran phase 2B study demonstrates a sustained increase in bowel movement frequency in patients regardeless of duration of opioid-induced constipation

Vickery, Ross G.; Webster, Lynn R.; Li, Y.; Singla, Neeraj; Canafax, Daniel M.

doi:10.1016/j.jpain.2014.01.317

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most prevalent AEs were GI related, were associated with treatment initiation, and were mild to moderate in nature. 63 There has been no registration of axelopran starting phase 3 trials to date.…”

Section: Bevenopranmentioning

confidence: 99%

“…At week 5, the mean change from baseline in weekly complete SBMs for axelopran patients with <5 years of OIC ranged from 1.7 to 2.3 vs 0.7, and 1.2 to 3.3 vs 0.6, respectively, for axelopran vs placebo with OIC ≥5 years. The most prevalent AEs were GI related, were associated with treatment initiation, and were mild to moderate in nature 63 . There has been no registration of axelopran starting phase 3 trials to date.…”

Section: Other Drugs In Development or Under Evaluationmentioning

confidence: 99%

See 1 more Smart Citation

New developments in the treatment of opioid‐induced gastrointestinal symptoms

2018

View full text Add to dashboard Cite

Chronic pain affects a large part of the global population, leading to an increase of opioid use. Opioid-induced constipation (OIC), a highly prevalent adverse effect of opioid use, has a major impact on patients’ quality of life. Thanks to the introduction of new drugs for chronic constipation, which can also be used in OIC, and the development of peripherally acting mu-opioid receptor blockers, specifically for use in OIC, therapeutic options have seen major development. This review summarises current and emerging treatment options for OIC based on an extensive bibliographical search. Efficacy data for laxatives, lubiprostone, prucalopride, linaclotide, oxycodone/naloxone combinations, methylnaltrexone, alvimopan, naloxegol, naldemedine, axelopran, and bevenopran in OIC are summarised.

show abstract

Section: Bevenopranmentioning

confidence: 99%

Section: Other Drugs In Development or Under Evaluationmentioning

confidence: 99%